Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Kristensen, L. E., Karlsson, J. A., Englund, M., Petersson, I. F., Saxne, T., & Geborek, P. 62(10):1362--1369. doi abstract bibtex OBJECTIVE: To examine clinical characteristics as possible predictors of long-term treatment continuation with adalimumab, etanercept, and infliximab in ankylosing spondylitis (AS) patients who had never taken biologics treated in clinical practice. METHODS: Patients in southern Sweden with active AS starting biologic therapy for the first time between October 1999 and December 2008 (n = 243, 75% men) were included in a structured clinical followup over 2 years. Patients with clinical spondylitis had not responded to at least 2 nonsteroidal antiinflammatory drugs, whereas patients who also had peripheral arthritis (n = 121) had additionally failed at least 1 conventional disease-modifying antirheumatic drug (DMARD) treatment course. The mean ± SD age at inclusion was 43 ± 12 years, with a mean ± SD disease duration prior to treatment of 16 ± 12 years. RESULTS: The 2-year drug continuation rate was 74%. Male sex (hazard ratio [HR] of premature discontinuation 0.36 [95% confidence interval (95% CI) 0.19-0.68]) and the presence of peripheral arthritis (HR 0.49 [95% CI 0.27-0.88]) were found to be significant predictors of better drug survival. Furthermore, a trend was seen for more favorable drug continuation on treatment with etanercept as compared with infliximab (HR 0.50 [95% CI 0.25-1.04], P = 0.062), whereas no differences were found comparing the 3 anti-tumor necrosis factor agents in other ways. Higher baseline C-reactive protein level (HR 0.99 [95% CI 0.97-1.00], P = 0.12) and concomitant treatment with nonbiologic DMARDs (HR 0.61 [95% CI 0.34-1.10], P = 0.10) also showed trends to entail better drug adherence. CONCLUSION: AS patients in this study have an excellent 2-year drug survival rate of 74%. Significant predictors for treatment continuation in this study were male sex and the presence of peripheral arthritis.
@article{kristensen_presence_2010,
title = {Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register},
volume = {62},
issn = {2151-4658},
doi = {10.1002/acr.20258},
shorttitle = {Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis},
abstract = {{OBJECTIVE}: To examine clinical characteristics as possible predictors of long-term treatment continuation with adalimumab, etanercept, and infliximab in ankylosing spondylitis ({AS}) patients who had never taken biologics treated in clinical practice.
{METHODS}: Patients in southern Sweden with active {AS} starting biologic therapy for the first time between October 1999 and December 2008 (n = 243, 75\% men) were included in a structured clinical followup over 2 years. Patients with clinical spondylitis had not responded to at least 2 nonsteroidal antiinflammatory drugs, whereas patients who also had peripheral arthritis (n = 121) had additionally failed at least 1 conventional disease-modifying antirheumatic drug ({DMARD}) treatment course. The mean ± {SD} age at inclusion was 43 ± 12 years, with a mean ± {SD} disease duration prior to treatment of 16 ± 12 years.
{RESULTS}: The 2-year drug continuation rate was 74\%. Male sex (hazard ratio [{HR}] of premature discontinuation 0.36 [95\% confidence interval (95\% {CI}) 0.19-0.68]) and the presence of peripheral arthritis ({HR} 0.49 [95\% {CI} 0.27-0.88]) were found to be significant predictors of better drug survival. Furthermore, a trend was seen for more favorable drug continuation on treatment with etanercept as compared with infliximab ({HR} 0.50 [95\% {CI} 0.25-1.04], P = 0.062), whereas no differences were found comparing the 3 anti-tumor necrosis factor agents in other ways. Higher baseline C-reactive protein level ({HR} 0.99 [95\% {CI} 0.97-1.00], P = 0.12) and concomitant treatment with nonbiologic {DMARDs} ({HR} 0.61 [95\% {CI} 0.34-1.10], P = 0.10) also showed trends to entail better drug adherence.
{CONCLUSION}: {AS} patients in this study have an excellent 2-year drug survival rate of 74\%. Significant predictors for treatment continuation in this study were male sex and the presence of peripheral arthritis.},
pages = {1362--1369},
number = {10},
journaltitle = {Arthritis Care \& Research},
shortjournal = {Arthritis Care Res (Hoboken)},
author = {Kristensen, L. E. and Karlsson, J. A. and Englund, M. and Petersson, I. F. and Saxne, T. and Geborek, P.},
date = {2010-10},
pmid = {20506310},
keywords = {Adalimumab, Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cohort Studies, Etanercept, Female, Follow-Up Studies, Humans, Immunoglobulin G, Infliximab, Male, Middle Aged, Osteoarthritis, Predictive Value of Tests, Prospective Studies, Receptors, Tumor Necrosis Factor, Registries, Sex Factors, Spondylitis, Ankylosing, Sweden, Treatment Outcome, Tumor Necrosis Factor-alpha}
}
Downloads: 0
{"_id":"mvr35LiXQXciEvPty","bibbaseid":"kristensen-karlsson-englund-petersson-saxne-geborek-presenceofperipheralarthritisandmalesexpredictingcontinuationofantitumornecrosisfactortherapyinankylosingspondylitisanobservationalprospectivecohortstudyfromthesouthswedisharthritistreatmentgroupregister","downloads":0,"creationDate":"2017-03-31T11:02:37.025Z","title":"Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register","author_short":["Kristensen, L. E.","Karlsson, J. A.","Englund, M.","Petersson, I. F.","Saxne, T.","Geborek, P."],"year":null,"bibtype":"article","biburl":"http://clinicalepidemiology.se/ClinEpi_LU.bib","bibdata":{"bibtype":"article","type":"article","title":"Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register","volume":"62","issn":"2151-4658","doi":"10.1002/acr.20258","shorttitle":"Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis","abstract":"OBJECTIVE: To examine clinical characteristics as possible predictors of long-term treatment continuation with adalimumab, etanercept, and infliximab in ankylosing spondylitis (AS) patients who had never taken biologics treated in clinical practice. METHODS: Patients in southern Sweden with active AS starting biologic therapy for the first time between October 1999 and December 2008 (n = 243, 75% men) were included in a structured clinical followup over 2 years. Patients with clinical spondylitis had not responded to at least 2 nonsteroidal antiinflammatory drugs, whereas patients who also had peripheral arthritis (n = 121) had additionally failed at least 1 conventional disease-modifying antirheumatic drug (DMARD) treatment course. The mean ± SD age at inclusion was 43 ± 12 years, with a mean ± SD disease duration prior to treatment of 16 ± 12 years. RESULTS: The 2-year drug continuation rate was 74%. Male sex (hazard ratio [HR] of premature discontinuation 0.36 [95% confidence interval (95% CI) 0.19-0.68]) and the presence of peripheral arthritis (HR 0.49 [95% CI 0.27-0.88]) were found to be significant predictors of better drug survival. Furthermore, a trend was seen for more favorable drug continuation on treatment with etanercept as compared with infliximab (HR 0.50 [95% CI 0.25-1.04], P = 0.062), whereas no differences were found comparing the 3 anti-tumor necrosis factor agents in other ways. Higher baseline C-reactive protein level (HR 0.99 [95% CI 0.97-1.00], P = 0.12) and concomitant treatment with nonbiologic DMARDs (HR 0.61 [95% CI 0.34-1.10], P = 0.10) also showed trends to entail better drug adherence. CONCLUSION: AS patients in this study have an excellent 2-year drug survival rate of 74%. Significant predictors for treatment continuation in this study were male sex and the presence of peripheral arthritis.","pages":"1362--1369","number":"10","journaltitle":"Arthritis Care & Research","shortjournal":"Arthritis Care Res (Hoboken)","author":[{"propositions":[],"lastnames":["Kristensen"],"firstnames":["L.","E."],"suffixes":[]},{"propositions":[],"lastnames":["Karlsson"],"firstnames":["J.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Englund"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Petersson"],"firstnames":["I.","F."],"suffixes":[]},{"propositions":[],"lastnames":["Saxne"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Geborek"],"firstnames":["P."],"suffixes":[]}],"date":"2010-10","pmid":"20506310","keywords":"Adalimumab, Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cohort Studies, Etanercept, Female, Follow-Up Studies, Humans, Immunoglobulin G, Infliximab, Male, Middle Aged, Osteoarthritis, Predictive Value of Tests, Prospective Studies, Receptors, Tumor Necrosis Factor, Registries, Sex Factors, Spondylitis, Ankylosing, Sweden, Treatment Outcome, Tumor Necrosis Factor-alpha","bibtex":"@article{kristensen_presence_2010,\n\ttitle = {Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register},\n\tvolume = {62},\n\tissn = {2151-4658},\n\tdoi = {10.1002/acr.20258},\n\tshorttitle = {Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis},\n\tabstract = {{OBJECTIVE}: To examine clinical characteristics as possible predictors of long-term treatment continuation with adalimumab, etanercept, and infliximab in ankylosing spondylitis ({AS}) patients who had never taken biologics treated in clinical practice.\n{METHODS}: Patients in southern Sweden with active {AS} starting biologic therapy for the first time between October 1999 and December 2008 (n = 243, 75\\% men) were included in a structured clinical followup over 2 years. Patients with clinical spondylitis had not responded to at least 2 nonsteroidal antiinflammatory drugs, whereas patients who also had peripheral arthritis (n = 121) had additionally failed at least 1 conventional disease-modifying antirheumatic drug ({DMARD}) treatment course. The mean ± {SD} age at inclusion was 43 ± 12 years, with a mean ± {SD} disease duration prior to treatment of 16 ± 12 years.\n{RESULTS}: The 2-year drug continuation rate was 74\\%. Male sex (hazard ratio [{HR}] of premature discontinuation 0.36 [95\\% confidence interval (95\\% {CI}) 0.19-0.68]) and the presence of peripheral arthritis ({HR} 0.49 [95\\% {CI} 0.27-0.88]) were found to be significant predictors of better drug survival. Furthermore, a trend was seen for more favorable drug continuation on treatment with etanercept as compared with infliximab ({HR} 0.50 [95\\% {CI} 0.25-1.04], P = 0.062), whereas no differences were found comparing the 3 anti-tumor necrosis factor agents in other ways. Higher baseline C-reactive protein level ({HR} 0.99 [95\\% {CI} 0.97-1.00], P = 0.12) and concomitant treatment with nonbiologic {DMARDs} ({HR} 0.61 [95\\% {CI} 0.34-1.10], P = 0.10) also showed trends to entail better drug adherence.\n{CONCLUSION}: {AS} patients in this study have an excellent 2-year drug survival rate of 74\\%. Significant predictors for treatment continuation in this study were male sex and the presence of peripheral arthritis.},\n\tpages = {1362--1369},\n\tnumber = {10},\n\tjournaltitle = {Arthritis Care \\& Research},\n\tshortjournal = {Arthritis Care Res (Hoboken)},\n\tauthor = {Kristensen, L. E. and Karlsson, J. A. and Englund, M. and Petersson, I. F. and Saxne, T. and Geborek, P.},\n\tdate = {2010-10},\n\tpmid = {20506310},\n\tkeywords = {Adalimumab, Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cohort Studies, Etanercept, Female, Follow-Up Studies, Humans, Immunoglobulin G, Infliximab, Male, Middle Aged, Osteoarthritis, Predictive Value of Tests, Prospective Studies, Receptors, Tumor Necrosis Factor, Registries, Sex Factors, Spondylitis, Ankylosing, Sweden, Treatment Outcome, Tumor Necrosis Factor-alpha}\n}\n\n","author_short":["Kristensen, L. E.","Karlsson, J. A.","Englund, M.","Petersson, I. F.","Saxne, T.","Geborek, P."],"key":"kristensen_presence_2010","id":"kristensen_presence_2010","bibbaseid":"kristensen-karlsson-englund-petersson-saxne-geborek-presenceofperipheralarthritisandmalesexpredictingcontinuationofantitumornecrosisfactortherapyinankylosingspondylitisanobservationalprospectivecohortstudyfromthesouthswedisharthritistreatmentgroupregister","role":"author","urls":{},"keyword":["Adalimumab","Adult","Antibodies","Monoclonal","Antibodies","Monoclonal","Humanized","Cohort Studies","Etanercept","Female","Follow-Up Studies","Humans","Immunoglobulin G","Infliximab","Male","Middle Aged","Osteoarthritis","Predictive Value of Tests","Prospective Studies","Receptors","Tumor Necrosis Factor","Registries","Sex Factors","Spondylitis","Ankylosing","Sweden","Treatment Outcome","Tumor Necrosis Factor-alpha"],"downloads":0},"search_terms":["presence","peripheral","arthritis","male","sex","predicting","continuation","anti","tumor","necrosis","factor","therapy","ankylosing","spondylitis","observational","prospective","cohort","study","south","swedish","arthritis","treatment","group","register","kristensen","karlsson","englund","petersson","saxne","geborek"],"keywords":["adalimumab","adult","antibodies","monoclonal","antibodies","monoclonal","humanized","cohort studies","etanercept","female","follow-up studies","humans","immunoglobulin g","infliximab","male","middle aged","osteoarthritis","predictive value of tests","prospective studies","receptors","tumor necrosis factor","registries","sex factors","spondylitis","ankylosing","sweden","treatment outcome","tumor necrosis factor-alpha"],"authorIDs":["58de1314e37c0a4446000026"],"dataSources":["824aokLfuuJkJwfhw"]}